European Commission Approves Pfizer’s HYMPAVZI™ for Severe Hemophilia A or B

Nov 20, 2024, 09:04 AM

The European Commission has approved Pfizer’s HYMPAVZI™ (marstacimab) for the treatment of adults and adolescents with severe hemophilia A or B without inhibitors. This approval marks a significant advancement in the treatment options available for hemophilia patients, providing a new once-weekly therapy. Pfizer announced that the approval will benefit eligible patients in the European Union, offering a new solution for managing this chronic condition.